Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Status:
Terminated
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells
(CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial
infarction.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Capricor Inc.
Collaborators:
California Institute for Regenerative Medicine (CIRM) National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)